Physician profile
Mark P Snell
NPI 1427025600
$2,194.99
in general payments reported to CMS, 2019-2025
28 companies · $78.50 in 2025
The $78.50 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $749 · 2020: $186 · 2021: $147 · 2022: $519 · 2023: $126 · 2024: $389 · 2025: $78.50.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $594.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $593.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $331.93 | 2019-2024 | Breztri, Farxiga, Bevespi Aerosphere |
| Sunovion Pharmaceuticals INC. | $276.11 | 2019-2022 | |
| Lilly USA, LLC | $230.40 | 2021-2024 | Mounjaro, Zepbound, Jardiance |
| Otsuka America Pharmaceutical, INC. | $177.48 | 2022-2025 | Rexulti |
| Abbvie INC. | $142.11 | 2022-2024 | Vraylar |
| Amgen INC. | $120.75 | 2019-2024 | Otezla, Repatha |
| Sanofi-Aventis U.S. LLC | $104.11 | 2019-2022 | |
| Pfizer INC. | $102.67 | 2019-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $97.91 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $87.24 | 2019-2023 | |
| E.R. Squibb & Sons, L.L.C. | $80.03 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $59.27 | 2019-2022 | |
| Mylan Specialty L.P. | $59.27 | 2019-2022 | |
| Neurocrine Biosciences, INC. | $50.20 | 2023-2024 | Ingrezza |
| Abbott Laboratories | $38.81 | 2022-2024 | Freestyle Libre |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $38.24 | 2019-2024 | Ozempic, Rybelsus |
| Janssen Pharmaceuticals, INC | $26.75 | 2019-2022 | |
| Daiichi Sankyo INC. | $19.25 | 2019 | |
| Astellas Pharma US INC | $19.24 | 2019 | |
| Medtronic, INC. | $17.25 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $17.13 | 2023 | |
| Dexcom, INC. | $16.47 | 2023 | Dexcom G6 Transmitter |
| Phathom Pharmaceuticals, INC. | $14.98 | 2024 | Voquezna |
| Lundbeck LLC | $14.71 | 2022 | |
| Exact Sciences Corporation | $13.99 | 2024 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $13.80 | 2019 | |
| Amarin Pharma, INC. | $13.16 | 2020 | |
| Glaxosmithkline, LLC. | $11.73 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Snell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.